These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 6787637)

  • 1. Fluphenazine pharmacokinetics and therapeutic response.
    Dysken MW; Javaid JI; Chang SS; Schaffer C; Shahid A; Davis JM
    Psychopharmacology (Berl); 1981; 73(3):205-10. PubMed ID: 6787637
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Relation of plasma fluphenazine levels to treatment response and extrapyramidal side effects in first-episode schizophrenic patients.
    Koreen AR; Lieberman J; Alvir J; Chakos M; Loebel A; Cooper T; Kane J
    Am J Psychiatry; 1994 Jan; 151(1):35-9. PubMed ID: 8267132
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fluphenazine plasma levels, dosage, efficacy, and side effects.
    Levinson DF; Simpson GM; Lo ES; Cooper TB; Singh H; Yadalam K; Stephanos MJ
    Am J Psychiatry; 1995 May; 152(5):765-71. PubMed ID: 7726317
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fluphenazine enanthate and fluphenazine decanoate in the treatment of schizophrenic outpatients: extrapyramidal symptoms and therapeutic effect.
    Chouinard G; Annable L; Ross-Chouinard A
    Am J Psychiatry; 1982 Mar; 139(3):312-8. PubMed ID: 6120655
    [No Abstract]   [Full Text] [Related]  

  • 5. Acute extrapyramidal reactions with fluphenazine hydrochloride and fluphenazine decanoate.
    Gelenberg AJ; Doller JC; Schooler NR; Mieske M; Severe J; Mandel MR
    Am J Psychiatry; 1979 Feb; 136(2):217-9. PubMed ID: 367182
    [No Abstract]   [Full Text] [Related]  

  • 6. Pharmacokinetics of haloperidol and fluphenazine decanoates in chronic schizophrenia.
    Wiles DH; McCreadie RG; Whitehead A
    Psychopharmacology (Berl); 1990; 101(2):274-81. PubMed ID: 2349370
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of clinical pharmacokinetics on neuroleptic therapy in patients with schizophrenia.
    Midha KK; Hubbard JW; Marder SR; Marshall BD; Van Putten T
    J Psychiatry Neurosci; 1994 Jul; 19(4):254-64. PubMed ID: 7918346
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Depressive and extrapyramidal symptoms and clinical effects: a trial of fluphenazine versus flupenthixol in maintenance of schizophrenic out-patients.
    Knights A; Okasha MS; Salih MA; Hirsch SR
    Br J Psychiatry; 1979 Dec; 135():515-23. PubMed ID: 394794
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fluphenazine plasma levels in patients receiving low and conventional doses of fluphenazine decanoate.
    Marder SR; Hawes EM; Van Putten T; Hubbard JW; McKay G; Mintz J; May PR; Midha KK
    Psychopharmacology (Berl); 1986; 88(4):480-3. PubMed ID: 3085136
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Double-blind study of domestic penfluridol and fluphenazine decanoate].
    Shu L
    Zhonghua Shen Jing Jing Shen Ke Za Zhi; 1983 Jun; 16(3):141-5. PubMed ID: 6653230
    [No Abstract]   [Full Text] [Related]  

  • 11. Patients at risk of developing severe side effects from depot fluphenazine treatment.
    Blum A
    Am J Psychiatry; 1980 Feb; 137(2):254-5. PubMed ID: 7352591
    [No Abstract]   [Full Text] [Related]  

  • 12. Fluphenazine plasma levels and clinical response.
    Mavroidis ML; Kanter DR; Hirschowitz J; Garver DL
    J Clin Psychiatry; 1984 Sep; 45(9):370-3. PubMed ID: 6381472
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Fluspirilen and fluphenazine in schizophrenic patients. Comparative study].
    Magnus RV
    MMW Munch Med Wochenschr; 1980 Dec; 122(49):1758-60. PubMed ID: 6779147
    [No Abstract]   [Full Text] [Related]  

  • 14. Double-blind comparison of haloperidol decanoate and fluphenazine decanoate effectiveness, side-effects, dosage and serum levels during a six months' treatment for relapse prevention.
    Kissling W; Möller HJ; Walter K; Wittmann B; Krueger R; Trenk D
    Pharmacopsychiatry; 1985 May; 18(3):240-5. PubMed ID: 4011672
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A double-blind dose-reduction trial of fluphenazine decanoate for chronic, unstable schizophrenic patients.
    Inderbitzin LB; Lewine RR; Scheller-Gilkey G; Swofford CD; Egan GJ; Gloersen BA; Vidanagama BP; Waternaux C
    Am J Psychiatry; 1994 Dec; 151(12):1753-9. PubMed ID: 7977881
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The use of fluphenazine enanthate in psychotic patients.
    Routsonis KG; Photiadis H
    Curr Ther Res Clin Exp; 1973 Mar; 15(3):92-6. PubMed ID: 4196232
    [No Abstract]   [Full Text] [Related]  

  • 17. Intermittent pimozide versus fluphenazine decanoate as maintenance therapy in chronic schizophrenia.
    McCreadie RG; Dingwall JM; Wiles DH; Heykants JJ
    Br J Psychiatry; 1980 Dec; 137():510-7. PubMed ID: 7011468
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fluphenazine decanoate, oral fluphenazine, and placebo in the treatment of remitted schizophrenics. II. Rating scale data [proceedings].
    Rifkin A; Quitkin F; Kane J; Klein DF
    Psychopharmacol Bull; 1977 Apr; 13(2):49-50. PubMed ID: 323910
    [No Abstract]   [Full Text] [Related]  

  • 19. Correlation of fluphenazine plasma levels versus clinical response in patients: a pilot study.
    Dudley J; Rauw G; Hawes EM; Keegan DL; Midha KK
    Prog Neuropsychopharmacol Biol Psychiatry; 1983; 7(4-6):791-5. PubMed ID: 6686710
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Plasma fluphenazine levels by radioimmunoassay in schizophrenic patients treated with depot injections of fluphenazine decanoate.
    Wiles DH; Gelder MG
    Br J Clin Pharmacol; 1979 Dec; 8(6):565-70. PubMed ID: 533577
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.